Aricept (donepezil hydrochloride)

DRUG4 trials

Sponsors

Eisai Inc.

Conditions

Cognitive DysfunctionDown SyndromeMigraine HeadacheMild Cognitive Impairment

Phase 2

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

CompletedNCT01146509

Eisai Inc.Migraine Headache

Start: 2003-01-31End: 2007-03-31Updated: 2012-12-10

Phase 3

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

TerminatedNCT00754052

Eisai Inc.Cognitive Dysfunction, Down Syndrome

Start: 2008-09-30End: 2008-12-31Updated: 2018-04-23

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

TerminatedNCT00754013

Eisai Inc.Cognitive Dysfunction, Down Syndrome

Start: 2008-09-30End: 2008-12-31Updated: 2020-01-28

Phase 4

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

CompletedNCT00934375

Eisai Inc.Mild Cognitive Impairment

Start: 2006-02-28End: 2007-09-30Updated: 2014-01-14